Jackson Hole Capital Partners LLC Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Jackson Hole Capital Partners LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 99,009 shares of the biopharmaceutical company’s stock after selling 5,007 shares during the quarter. Jackson Hole Capital Partners LLC’s holdings in Pfizer were worth $2,627,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter worth $26,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the fourth quarter worth $28,000. Finally, Noble Wealth Management PBC purchased a new position in shares of Pfizer in the fourth quarter worth $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.71 on Friday. The stock has a 50-day simple moving average of $26.30 and a two-hundred day simple moving average of $27.24. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $151.35 billion, a PE ratio of 18.94, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date was Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.44%. Pfizer’s dividend payout ratio is 121.99%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PFE. Guggenheim restated a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Finally, Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.